CA2387559A1 - Complexe de recepteurs peptidiques n-formyle et d'agents de modification du mecanisme de signalisation de la proteine kinase g - Google Patents

Complexe de recepteurs peptidiques n-formyle et d'agents de modification du mecanisme de signalisation de la proteine kinase g Download PDF

Info

Publication number
CA2387559A1
CA2387559A1 CA002387559A CA2387559A CA2387559A1 CA 2387559 A1 CA2387559 A1 CA 2387559A1 CA 002387559 A CA002387559 A CA 002387559A CA 2387559 A CA2387559 A CA 2387559A CA 2387559 A1 CA2387559 A1 CA 2387559A1
Authority
CA
Canada
Prior art keywords
cell
protein
pro
inflammatory
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002387559A
Other languages
English (en)
Inventor
James A. Clagett
Craig Palmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mowycal Lending LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2387559A1 publication Critical patent/CA2387559A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un procédé d'inhibition d'une réponse pro-inflammatoire d'une cellule sanguine périphérique, humaine, mononucléaire ou polymorphonucléaire, ou d'une cellule tissulaire fixe. Ce procédé consiste à mettre en contact la cellule avec un agent pro-inflammatoire, afin de stimuler une réponse pro-inflammatoire, puis à mettre la cellule en contact avec un agent de modification du mécanisme de signalisation de la protéine kinase G, de manière à inhiber les mécanismes de transduction du signal de réponse inflammatoire, induits par la protéine G. L'invention concerne un complexe de récepteurs, dans lequel un agent de modification du mécanisme de signalisation de la protéine G kinase se lie à un récepteur de surface cellulaire d'une cellule sanguine périphérique humaine, mononucléaire ou polymorphonucléaire, qui a été stimulée par un agent pro-inflammatoire.
CA002387559A 1999-10-15 2000-10-12 Complexe de recepteurs peptidiques n-formyle et d'agents de modification du mecanisme de signalisation de la proteine kinase g Abandoned CA2387559A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15967799P 1999-10-15 1999-10-15
US60/159,677 1999-10-15
PCT/US2000/028183 WO2001029069A1 (fr) 1999-10-15 2000-10-12 Complexe de recepteurs peptidiques n-formyle et d'agents de modification du mecanisme de signalisation de la proteine kinase g

Publications (1)

Publication Number Publication Date
CA2387559A1 true CA2387559A1 (fr) 2001-04-26

Family

ID=22573520

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002387559A Abandoned CA2387559A1 (fr) 1999-10-15 2000-10-12 Complexe de recepteurs peptidiques n-formyle et d'agents de modification du mecanisme de signalisation de la proteine kinase g

Country Status (16)

Country Link
EP (1) EP1222199A4 (fr)
JP (1) JP2004507441A (fr)
KR (1) KR20020057972A (fr)
CN (1) CN100497374C (fr)
AU (1) AU8014200A (fr)
BR (1) BR0014742A (fr)
CA (1) CA2387559A1 (fr)
CZ (1) CZ20021342A3 (fr)
EA (1) EA200200451A1 (fr)
HU (1) HUP0203688A2 (fr)
IL (1) IL149125A0 (fr)
MX (1) MXPA02003782A (fr)
NO (1) NO20021732L (fr)
PL (1) PL356096A1 (fr)
WO (1) WO2001029069A1 (fr)
ZA (1) ZA200202937B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030220258A1 (en) 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
US6844315B2 (en) 1998-05-20 2005-01-18 Erasmus Universiteit Rotterdam Immunoregulator
EP1138692A1 (fr) 2000-03-29 2001-10-04 Erasmus Universiteit Rotterdam Fragments de gonadotrophine chorionique humaine comme immunorégulateurs
US8680059B2 (en) 1998-05-20 2014-03-25 Biotempt B.V. Oligopeptide acetate and formulations thereof
USRE43279E1 (en) 2000-03-29 2012-03-27 Biotemp B.V. Compositions capable of reducing elevated blood urea concentration
US7358330B2 (en) 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
EP1300418A1 (fr) * 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Régulation génétique par des oligopeptides
US7786084B2 (en) 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
WO2004100978A1 (fr) * 2003-05-13 2004-11-25 Medvet Science Pty. Ltd. Procede de modulation de la transmigration cellulaire et agents utilises a cet effet
SG163567A1 (en) 2005-07-05 2010-08-30 Biotempt Bv Treatment of tumors
EP1864692A1 (fr) 2006-06-07 2007-12-12 Biotempt B.V. Utilisation de peptides pour la protection contre les radiolésions
US20110082091A1 (en) * 2009-09-28 2011-04-07 Theramab Gmbh Method for Preclinical Testing of Immunomodulatory Drugs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002516820A (ja) * 1997-11-13 2002-06-11 ヒスタテク・エルエルシー 低分子量ペプチド及び喘息及び炎症の治療方法

Also Published As

Publication number Publication date
CN100497374C (zh) 2009-06-10
HUP0203688A2 (hu) 2003-02-28
EA200200451A1 (ru) 2002-10-31
EP1222199A1 (fr) 2002-07-17
CN1633447A (zh) 2005-06-29
AU8014200A (en) 2001-04-30
IL149125A0 (en) 2002-11-10
NO20021732D0 (no) 2002-04-12
CZ20021342A3 (cs) 2003-01-15
ZA200202937B (en) 2003-09-23
WO2001029069A1 (fr) 2001-04-26
BR0014742A (pt) 2002-08-27
NO20021732L (no) 2002-06-12
KR20020057972A (ko) 2002-07-12
JP2004507441A (ja) 2004-03-11
EP1222199A4 (fr) 2003-03-12
PL356096A1 (en) 2004-06-14
MXPA02003782A (es) 2002-12-13

Similar Documents

Publication Publication Date Title
Stevenson et al. Myristyl acylation of the tumor necrosis factor alpha precursor on specific lysine residues.
US7566767B2 (en) Synthetic peptides and methods of use for autoimmune disease therapies
Offermanns et al. Gq and G11 are concurrently activated by bombesin and vasopressin in Swiss 3T3 cells
CA2387559A1 (fr) Complexe de recepteurs peptidiques n-formyle et d'agents de modification du mecanisme de signalisation de la proteine kinase g
KR100457350B1 (ko) ＩｇＥ-의존적 히스타민 방출인자(ＨＲＦ)의 수용체,ＨＲＦ 결합 펩타이드 및 그들을 코딩하는 핵산, 및그들의 용도
Goetzl et al. Structural determinants of the eosinophil: chemotactic activity of the acidic tetrapeptides of eosinophil chemotactic factor of anaphylaxis.
Balboni et al. Opioid diketopiperazines: synthesis and activity of a prototypic class of opioid antagonists
Kozlov et al. A sea anemone polypeptide toxin inhibiting the ASIC3 acid-sensitive channel
JP2002528389A (ja) Ｉｌ−２及びその類似体から誘導される抗炎症性ペプチド
Navolotskaya et al. Effect of synthetic β-endorphin-like peptide immunorphin on human T lymphocytes
Szatmári et al. Influence of degradation on binding properties and biological activity of endomorphin 1
US7132505B1 (en) Polypeptide inhibiting a proton-gated Na+ channel, a nucleic acid coding for such polypeptide and a method of manufacturing an ASIC1a channel blocker
EP1280895A2 (fr) Polypeptide inhibant un canal sodique a porte protonique
Radel et al. Structural and functional characterization of the human formyl peptide receptor ligand-binding region
Jinsmaa et al. Potent in vivo antinociception and opioid receptor preference of the novel analogue [Dmt1] endomorphin-1
CA2152141A1 (fr) Antagonistes de la proteine mcp-1 de monocyte
Landis et al. Synthesis of highly. mu. and. delta. opioid receptor-selective peptides containing a photoaffinity group
RU2163242C2 (ru) Циклогексапептиды, их смеси, способ их получения
Biondi et al. Opioid peptides: synthesis and biological activity of new endomorphin analogues
AU2001264892B2 (en) Modulaton of alpha-6 integrin-mediated responses
Rita et al. Effects of synthetic peptides on the inflammatory response and their therapeutic potential
HU205143B (en) Process for producing peptides having t cell suppressor activity and pharmaceutical compositions comprising same
AU2001264892A1 (en) Modulaton of alpha-6 integrin-mediated responses
Blondelle et al. All d‐amino acid hexapeptide inhibitors of melittin's cytolytic activity derived from synthetic combinatorial libraries
US4749685A (en) Immunosuppressive peptides

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued